Last update:
Oncology & Cancer news
Oncology & Cancer
Tricking tumors into marking themselves for destruction with focused ultrasound
USC biomedical engineers have found a way to make a solid tumor paint a target on its own back in order to train the body's immune system to find and destroy it.
4 hours ago
0
32
Oncology & Cancer
Preoperative radiation may improve antitumor immune response in most common form of breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led ...
5 hours ago
0
0
Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer
Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition ...
5 hours ago
0
0
Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median ...
5 hours ago
0
0
Octopus-inspired 3D micro-LEDs pave the way for selective pancreatic cancer therapy
Conventional pancreatic cancer treatments face a critical hurdle due to the dense tumor microenvironment (TME). This biological barrier surrounds the tumor, severely limiting the infiltration of chemotherapy agents and immune ...
3 hours ago
0
0
Daily scans during prostate cancer could guide changes to treatment, reduce the risk of side effects, study suggests
Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests.
8 hours ago
0
0
Making cancer screening more accessible to underserved groups
New research from the University of Aberdeen and the Grampian Regional Equality Council (GREC) has outlined ways to make cancer screening services more accessible to people who may be underserved by the health care system. ...
4 hours ago
0
0
Valvular heart disease is common in cancer patients but interventions can improve survival
Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat valvular heart disease significantly improved survival.
8 hours ago
0
0
Research strengthens evidence linking alcohol use to cancer
As Americans gear up for the holiday season, new research offers a timely reminder to reflect on the long-term health effects of raising a celebratory glass—or two. Alcohol is known to increase the risk of several cancers ...
4 hours ago
0
0
A paper-based technology could transform cancer drug testing
Researchers at New York University Abu Dhabi (NYUAD) have developed Spheromatrix, a simple and low-cost technology that enables tumor models to be grown, frozen, and stored for future use in cancer drug testing.
20 hours ago
0
14
Cell-free DNA could detect adverse events from immunotherapy
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns Hopkins Kimmel Cancer ...
21 hours ago
0
0
Off-the-shelf immunotherapy offers new hope for toughest myeloma
A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma—one of the most ...
21 hours ago
0
0
New cancer therapy brings remission for patients with deadly T-cell leukemia
A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by an innovative form of immune therapy.
21 hours ago
0
0
Next-generation CAR T cells show stronger, safer response in animal models
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, ...
Dec 10, 2025
0
0
GLP-1 medications show little effect on cancer, study shows
A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.
22 hours ago
0
0
Mobile DNA elements reveal their role in lung cancer progression
Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, ...
Dec 10, 2025
0
0
Real-time imaging captures what happens to cancer cells arriving in the brain
Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death. Brain metastasis is ...
Dec 10, 2025
0
0
A multimodal AI model may improve recurrence risk stratification in early breast cancer
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, ...
Dec 10, 2025
0
0
Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending ...
Dec 10, 2025
0
0
FDA approves expanded indication for Jaypirca
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory ...
Dec 10, 2025
0
0
Novel endocrine therapy reduces the risk of breast cancer recurrence
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1–3) ...
Dec 10, 2025
0
0
Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care ...
Dec 10, 2025
0
0
Socioeconomic factors, comorbidities tied to late-onset depression in long-term cancer survivors
Socioeconomic vulnerability and multiple medical comorbidities are risk factors for late-onset depression among long-term cancer survivors, according to a study published in JAMA Network Open.
Dec 10, 2025
0
0
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy ...
Dec 10, 2025
0
0
Cancer signaling discovery reveals potential path to more effective cancer drugs
Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert Medical School of Brown ...
Dec 10, 2025
0
0
